Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalent doses study of nalbuphine and sufentanil for colonoscopy under bispectral index monitoring
ChiCTR-IPR-16009184Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine and sufentanil, sponsored by West China Hospital of Sichuan University. Primary endpoints: Analgesic effect during colonoscopy, Safety outcomes and 1 more. Started Dec 2015; status: recruiting.
02
Drugs
nalbuphinesufentanil
Beyond the preview
Go deeper on ChiCTR-IPR-16009184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009184.